Regarding CRC, although KRAS mutations occur as an early event in about 50% of cases, they are probably not the primary initiating events being but the loss of APC or mutations in β-catenin in mismatch repair deficient tumors. This evidence concerns the gene KRAS and colorectal carcinoma.